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related to both total time and time after Katrina. CONCLUSIONS: Hurricane 
Katrina was found to be a key factor in the significant decrease in the number of 
patients that received anti-epileptic medications post-Hurricane Katrina. This 
may also explain why there were significant decreases in the numbers of ER 
visits, anti-epileptic medications obtained and the average cost of paid claims for 
anti-epileptic drugs. In effect, Katrina had both short- and long-term negative 
effects on epileptic patients’ access to care.  
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OBJECTIVES: Hurricane Katrina was the deadliest hurricane in the United States 
in seven decades and the most expensive natural disaster in American history. 
The aftermath of this catastrophic event has provided a window to quantify its 
impact on continuously eligible epilepsy patients in the Louisiana Medicaid 
population with respect to outpatient visits, inpatient visits and changes in 
providers specialty categories pre- and post Hurricane Katrina (August 29, 2004-
August 28, 2007). METHODS: This study was a population-based retrospective 
analysis of the Louisiana Medicaid database. Segmented regression analysis was 
applied to the longitudinal data to analyze changes in patients with at least one 
outpatient-visit and inpatient visits made by the providers and the average cost 
of the visits. The dependent variables were regressed against 1) total time 
(months); 2) Katrina as a discrete event; and 3) time post-Katrina (months). A chi-
square analysis was performed to determine the change in provider specialty 
categories at α = 0.05 pre and post Hurricane Katrina. RESULTS: Results of 
segmented regression analysis revealed that time variables, total and time post-
Katrina, were significant for the average cost of paid claims submitted by 
outpatient providers. There was no significant increase in number of patients 
with inpatient admissions (npre=97, npost1=119, npost2=137) and no significant 
change in average cost of paid claims submitted by inpatient providers but the 
number of inpatient visits (pre=298, post1=435, post2=567) increased 
significantly. Visits to neurologists decreased by a significant number (npre=147, 
npost1=91, npost2=82) pre- and post-Katrina. Also, the number of primary care 
physicians visits increased from pre- to post-period. CONCLUSIONS: Hurricane 
Katrina may be a key factor in increase in number of inpatient visits made by the 
providers. Decrease of visits to neurologists due to displacement post-Hurricane 
Katrina may be a reason for increasing patient visits to primary care physicians.  
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OBJECTIVES: This study aims to examine vaccine effectiveness (VE) estimates 
used in cost-effectiveness studies that compared the 23-valent pneumococcal 
polysaccharide vaccine (PPSV23) to the 13-valent pneumococcal conjugate 
vaccine (PCV13) for adults, and assess how differences in VE estimates affect the 
estimated incremental cost-effectiveness ratios (ICER). METHODS: A targeted 
literature review was performed to identify cost-effectiveness analyses of PPSV23 
vs. PCV13 in adults. A comparative assessment of input parameter values used in 
these analyses was performed and their relationship to model results was 
examined. RESULTS: Four models that evaluated the cost-effectiveness of 
PPSV23 versus PCV13 in adults were identified. All models estimated that PPSV23 
protected against more vaccine-type infections than PCV13. However, each 
model assumed different VE estimates in preventing invasive pneumococcal 
disease (IPD) and non-bacteremic pneumococcal pneumonia (NBPP). PCV13 VE 
estimates for adults were derived from pediatric clinical efficacy data either 
directly or via Delphi panels. PPSV23 VE estimates were obtained from meta-
analyses of randomized trials or observational studies in adults either directly or 
with Delphi panels. For vaccine-type IPD, base-case VE estimates were relatively 
consistent among the studies for immunocompetent adults (PPSV23: 57%-93%; 
PCV13: 61%-94%) but varied for immunocompromised adults (PPSV23: 0%-18%; 
PCV13: 48%-71%). For vaccine-type NBPP, VE estimates varied for 
immunocompetent adults (PPSV23: 0%-60%; PCV13: 50%-74%) and 
immunocompromised adults (PPSV23: 0%, PCV13: 6%-35%). Model results 
showed that PCV13 had lower ICERs than PPSV23 when PPSV23 efficacy for NBPP 
was assumed to be 0%, while PPSV23 had lower ICERs than PCV13 when PPSV23 
was assumed effective in preventing NBPP in immunocompetent adults. 
CONCLUSIONS: Cost-effectiveness results for adult pneumococcal vaccination 
were highly sensitive to VE estimates. With the absence of head-to-head clinical 
efficacy data comparing PPSV23 to PCV13 and the influence these data have on 
model results, sensitivity analyses are needed when considering potential policy 
implications of these cost-effectiveness studies.  
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OBJECTIVES: As compared to non-diabetics, diabetic patients are more likely to 
be hospitalized with longer hospital stay. A variety of risk adjustment (RA) 
measures are available, which makes it difficult to select the best performing 
measure to predict outcomes. The aim of this study is to compare performance 
of risk adjustment measures to predict in-hospital mortality and length of stay 
(LOS) in diabetic patients. METHODS: A retrospective cross-sectional study was 
conducted using the HCUP Nationwide inpatient Sample (NIS)-2009 data. All 
adults (age >18 years) diagnosed with Diabetes were included in the study. 
Charlson-Deyo Adaptation and Elixhauser Co-morbidity Index were constructed 
using the International Classification of Disease, 9th Revision, Clinical 
Modification (ICD-9-CM). Two proprietary measures (APR-DRG & Disease Staging) 
were compared with comorbidity measures for predicting in-hospital mortality 
and LOS. Logistic regression was used to predict in-hospital mortality and c-
statistics were used to assess the comparative performance of different models. 
Adjusted R2from Linear regression models was compared to do the same for the 
continuous outcome, LOS. RESULTS: The prevalence of diabetes was found to be 
28.2% with mortality rate of 2.09% and median LOS of 2.77 ± 0.01 days. Hospital 
stays were predominantly by white females (<65 years). Models containing APR-
DRG measure outperformed all other measures for both outcomes (in-hospital 
mortality, c-statistics=0.91-0.90 and; LOS, adjusted R2=0.172-0.163). The model 
containing all demographic variables along with APR-DRG and Elixhauser 
comorbidity index outperformed all other models for predicting in-hospital 
mortality (c-statistics=0.91) and LOS (Adjusted R2=0.172). CONCLUSIONS: The 
APR-DRG, being a clinical model, is superior to other comorbidity measures for 
risk-adjusting in-hospital mortality and LOS. Addition of comorbidity measures 
to APR-DRG improves the model performance when predicting in-hospital 
mortality and LOS.  
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OBJECTIVES: To develop a novel metric to evaluate the potential value of 
individualized care using traditional clinical trial data to prioritize patient 
centered outcomes research (PCOR). METHODS: Assume a head to head trial of 2 
treatments (A and B), patients are randomly assigned to either treatment and QA 
and QB are outcomes obtained. The joint distribution (QAB) is not available as 
patients can only be assigned to one treatment. However, the marginal 
distributions of QA and QB, as obtained in a standard clinical trial, represent a 
plausible range of heterogeneous treatment effects. The extent of these marginal 
distributions can be used to form a Jointness-Box (JB) bounding an expected 
range of individual potential outcomes. Graphically, in a plot of QA versus QB , 
where the 45-degree line represents the locus of equality, the JB represents the 
area enveloping the anticipated joint distribution of QA and QB. In our 
development, we examine conditions of JB dominance i.e. if the entire box is 
above or below the 45 degree line, and JB area i.e. proportion of the JB that falls 
above the 45 degree line. We used bootstrap methods, ordered statistics and 
percentile cutoffs to examine the likelihood of JB dominance, and confidence 
intervals for JB area across a range of starting assumptions and distributions. 
RESULTS: We found JB dominance is negatively correlated with the value of 
PCOR. The JB area versus PCOR is concave shaped with maximal PCOR when JB 
area = 0.5. Simulation analysis indicates that for normally distributed trial 
outcomes, JB estimates are conservative in terms of inference about 
heterogeneity, and exhibit maximal accuracy when JB area = 0.5. CONCLUSIONS: 
The JB metric developed allows analysts and decision makers to intuitively 
understand the potential value and impact of exploring heterogeneity within a 
PCOR context.  
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OBJECTIVES: Drug manufacturers often struggle with the decision to include 
patient-relevant outcome measures into clinical trials while also trying to satisfy 
the demands of regulators and payers. In oncologic indications, where the 
diagnosis and management of cancer can have a significant impact on survival 
and patient and quality of life (QoL), more focus is therefore being placed on the 
quality of extended survival for cancer patients. Here, we examine inclusion of 
patient reported outcomes (PROs) as primary or secondary QoL endpoints for the 
top ten oncology indications currently in Phase III development. METHODS: 
Pipeline drug candidates from Adis R&D Insight database were collected with 
clinical development details for all late-phase (Phase II/III or Phase III) drug 
candidates in the top ten oncology indications. Trial details were further 
examined via ClinicalTrials.gov. An analysis was then conducted to determine 
how frequently drug trials are incorporating patient-relevant outcomes into their 
clinical development programs. Results were categorized into five clustered PRO 
categories. RESULTS: Over 140 drug candidates and 304 clinical trials were 
identified. In these trials, only 11 included PROs as a primary endpoint. As 
secondary endpoints PROs were much more common, appearing 184 (60.5%) 
occasions. A total of 54 different PRO endpoints were utilized to measure QoL. 
Generic Non-Cancer measures (9.5%), Specific Non-Cancer measures (9.9%), 
General Cancer-Specific measures (16.1%), Symptom-Specific Cancer measures 
(6.3%), and Unspecified/General measures (18.8%) were utilized by 
manufacturers. EQ-5D was the most commonly specified measure (7.6%), 
followed by EORTC QLQ C30 (6.3%). CONCLUSIONS: Drug manufacturers are 
largely including PROs into oncology trials. However, the selection of measures is 
inconsistent and opportunities still exist to collect further QoL data by including 
PROs in trials where such measures are absent. Aligning the demands of payers, 
physicians and patients would help to incentivize a more standardized inclusion 
of PROs with greater frequently in oncology development programs  
